Testosterone Muscle
SEARCH

Advanced | Members

HOME    T-NATION FORUMS    TMUSCLE STORE     LOG IN
Store | Videos | Training Programs | Articles | Forums

Cy-BORG
Intelligent Drug and Nutrition Info


Coral Calcium Debunked

A: First of all, calcium is an important element and plays a role in many functions. Here are a few of them:

Muscle contraction

Enzyme activation

Regulation of release and storage of neurotransmitters and hormones

Uptake and binding of amino acids

Vitamin B12 absorption

Transmission of nerve impulses

Blood coagulation

Cell membrane permeability

However, all essential vitamins and minerals have important functions. It's not as if calcium is the only important element.

Anyhow, the infomercials you see on coral calcium make a great production about how necessary calcium is for bodily functions. This is true, but by reporting this info the commercials get people to start thinking, "Well, this stuff really is important so I'd better make sure I'm taking the best kind." In other words, it's just a marketing technique.

Then they go on to convince you that coral calcium is superior because it's "found in nature" and thus has greater biological value. Well, that's odd because last I had checked, calcium carbonate (found in Tums) is also found in nature.

They make claims that coral calcium is better absorbed and utilized when, in fact, there's no evidence whatsoever to support this claim. There isn't even a valid theoretical reason to expect higher bioavailability.

Now, is there any evidence that using calcium (in any form) will prolong life, prevent aging, prevent many metabolic disorders, and whatever else they claim in those ads? Not to my knowledge. However, there is evidence supporting the use of calcium in the following: colorectal cancer prevention, dysmenorrhea, hypercholesterolemia, hypertension, osteoporosis, and even premenstrual syndrome.

So, based on all this, I still suggest going with the cheaper carbonate salt of calcium found in Tums and other heartburn products. Stick with around 500 to 2000 mg/day. (1-21)


Finasteride: A Double-edged Sword?

A: I do have a theory. Finasteride inhibits DHT formation and I believe it's this decrease in intraprostatic DHT which causes the virulent or high-grade cancer. DHT itself has an estrogen-lowering effect in general and this includes the prostate.

Now, as TC so eloquently pointed out in his article, Estrogen's Dirty Little Secret, estrogen is a great mediator of cell growth and cancer formation in the prostate. Well, when you decrease intraprostatic DHT, you give rise to the possibility of having elevated intraprostatic estradiol levels.

On top of this, you also have Testosterone itself in the same, if not higher concentrations when using finasteride. Thus, you have androgen receptor binding and of course estrogen receptor binding which both seem to play a role in carcinogenesis in the prostate, with estrogen playing a greater role in my opinion.

Another contributing factor, although less likely, is that the increase in endogenous Testosterone from finasteride provides yet more substrate for estradiol formation, although after investigation I don't think this is really a factor. Basically, we need DHT for its anti-estrogenic properties.

So, in summary, I think the main reason this is happening is due to decreased intraprostatic DHT levels, which in turn allows for elevated intraprostatic estradiol and consequently increases the risk for high-grade prostate cancer. (22-29)


Melatonin: Good Sleep Aide or Miracle Drug?

A: Melatonin actually has some pretty solid evidence supporting its use as an anti-cancer agent. It's been shown to increase the effectiveness of chemotherapy as well as protect against radiation. It also showed benefit in those being treated for various types of metastatic, solid tumors (e.g. skin and lung cancers which were very resistant to other forms of treatment and deemed untreatable) with tamoxifen. Other studies had similar findings.

As far as its anti-aging effects, melatonin possesses free radical-scavenging properties, protecting cells from oxidative damage, so you could technically say it has "anti-aging" properties, although this can be said for just about any antioxidant.

However, another additional benefit may be that melatonin can inhibit nitric oxide synthase. Nitric oxide can have damaging effects on cells via its reaction with superoxide, which allows for the formation of peroxynitrite. This in turn stimulates lipid peroxidation and depletes glutathione concentrations. So, melatonin may help in a more indirect manner as well.

The common dosages for those with cancer are 40 to 50mg per day (taken at night) in combination with another anti-cancer drug. If using melatonin alone, use 20mg per day intramuscularly for two months and then begin taking 10mg per day orally. If using it as a prophylaxis or sleep aid, stick with 1-5mg a day before bed. Some people may find that 5mg is too much, so start out with 1mg and work your way from there to assess what amount works best for you.

Just as some "precautionary" side info, melatonin can have some effects that we bodybuilders and athletes may perceive as negative. For instance, it's been shown to cause statistically significant reductions in body temperature (.5-1.5° Fahrenheit). In reality though, this isn't that big of a deal, just some interesting info. Chronic ingestion of melatonin (1 gram per day) did cause suppression of serum LH in humans, but again, the dosages commonly employed are only a fraction of that so it's probably nothing to worry about. (30-48)


Lipo with a Needle?

A: Depending on which country you're in, Lipostabil, made by Aventis, may contain only phosphatidylcholine and is intended for injection, or it may also contain multivitamins and theophylline and be used orally (capsules) instead. Lipostabil in South Africa contains phosphatidycholine, vitamins, and adenosine phosphate and is intended for injection, but they also have an encapsulated version containing phosphatidylcholine, vitamins and theophylline.

Many countries have actually discontinued marketing or even making the product. However, I'm assuming this is because it was originally designed for other purposes (hyperlipidaemias, atherosclerosis, thromboembolism, etc.) and not for "fat reduction" and such.

Anyhow, since you specifically mentioned Europe, I believe every current formulation there only contains phosphatidylcholine and is available for injection. However, it could very well be that they're using the formulation with theophylline or a derivative thereof, along with vitamins and phosphatidylcholine. In my opinion, the latter actually has more merit to its purported effects. With a phosphodiesterase inhibitor like theophylline, we of course get an accumulation of cyclic AMP, which eventually leads to lipolysis in adipocytes.

The use of phosphatidylcholine, while playing an important role in fat metabolism, is a bit of a stretch. I'm guessing their theory is that the lecithin (phosphatidylcholine) is emulsifying the fat when injected and allowing it to be dispersed. In actuality, the combination of theophylline and lecithin is the combination that makes most sense in terms of people seeing reductions in fat mass after subcutaneous injection of such a product.

Still, until some validating research arises, I won't recommend people using this sort of treatment. Aside from that, theophylline isn't my first choice for phosphodiesterase inhibition as there are other methylxanthines out there that don't have the same toxicity issues.


The Worst Pre-Workout Stimulant

A: I've never really heard of this method nor would I ever advise anyone to use it. Caffeine can provide significant CNS stimulation as well, yet isn't anywhere near as addictive as nicotine. This isn't to say that nicotine has absolutely no medicinal value but for a "pre-workout stimulant" it's really not worth using as there are other viable alternatives available. Aside from that, nicotine may indirectly cause cancers.

I suppose that nicotine may be slightly more advantageous in terms of increasing strength prior to a workout due to its binding to nicotinic acetylcholine receptors, allowing for stronger muscle contractions. However, even if you're able to "kick" the nicotine addiction, you're more likely to experience a bout of depression thereafter.

Not only that, but it's possible that nicotine can cause desensitization and/or persistent inactivation of the nicotinic acetylcholine receptor. That means it's possible you could actually lose strength after continued use of the drug.

It's also been shown that while caffeine doesn't increase cortisol levels to a significant extent, nicotine does, so that's just one more reason not to use it for such a purpose. In short, using nicotine as a "pre-workout stimulant" is a bad idea. (49-56)


More Capsules for Big Ol' Boys?

A: Well, basing dosage only on body weight really isn't too accurate with many compounds. It's more accurate to take into account not only body weight but body surface area, plasma protein binding, extraction ratio, renal function, hepatic function (cytochrome P-450) and in some cases even cardiac function.

It's also important to realize that drugs are metabolized in places other than the liver and kidneys, like the GI tract, lungs, and even the skin. With that being said, it's easy to see how each individual can vary in terms of how they metabolize various drugs and how these can be influenced by our genes.

However, for the majority of people, functioning of the above is similar enough to where one dosage can be used in various sizes and sexes. Essentially though, this is where clinical pharmacokinetic data comes into play to help answer questions on dosing for a given drug. Again, while body weight does play a role, it's simply part of the total picture. This is why, for the most part, just about any drug you take will have the same prescribed dosage irrespective of size or sex. (Although, the sex portion has been the subject of debate by some pharmacologists.)

Anyhow, extreme variations in one of these factors, mainly hepatic and renal metabolism, is also why you tend to have some people who need varying dosages. For example, some 150 pound guys can tolerate 250 mg of ephedrine and 1000 mg of caffeine in a day without any negative side effects, while some 250 pound males can only tolerate a fraction of that dosage. With the particular compounds in HOT-ROX, it isn't really necessary to base the dosage on body weight. That's why we have the same recommended dosage irrespective of sex or size.


'Roids and Prostatitis

A: I'm not aware of any direct link between Testosterone use and prostatitis. In the majority of cases with those suffering from prostatitis, the cause is really not known. For a small fraction of those people, it appears to be due to bacterial infections.

With BPH (Benign Prostatic Hypertrophy) however, using Testosterone could contribute to such a condition. Those with BPH can sometimes experience prostatitis as a result.

So, if you have BPH and suspect that it stems from the use of androgens and have recently developed prostatitis, it may be a good idea to discontinue use for a while and see if that helps. If however, you have no symptoms of BPH and your physician has determined you don't have BPH, yet have prostatitis, I see no reason why you can't continue to use Testosterone as well as other androgens.


References Cited

1. Hofstad B, Almendingen K, Vatn M, et al. "Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and antioxidants." Digestion 1998; 59(2):148-156.

2. Duris I, Hruby D, Pekarkova B, et al. "Calcium chemoprevention in colorectal cancer. Hepatogastroenterology." 1996; 43(7):152-154.

3. Lipkin M & Newmark H. "Calcium and colon cancer (letter)." Nutr Rev 1993; 51(7):213-214.

4. Zimmerman J. "Does dietary calcium supplementation reduce the risk of colon cancer (letter)?" Nutr Rev 1993; 51(4):109-112.

5. Penland JG & Johnson PE. "Dietary calcium and manganese effects on menstrual cycle symptoms." Am J Obstet Gynecol 1993; 168(5):1417-1423.

6. Thys-Jacobs S, Ceccarelli S, Bierman A, et al. "Calcium supplementation in premenstrual syndrome: a randomized crossover trial." J Gen Intern Med 1989; 4(3):183-189.

7. Denke MA, Fox MM & Schulte MC. "Short-term dietary calcium fortification increases fecal saturated fat Content and reduces serum lipids in men." J Nutr 1993; 123(6):1047-1053.

8. Bell L, Halstenson CE, Halstenson CJ, et al. "Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia." Arch Intern Med 1992; 152(12):2441-2444.

9. Karanja N, Morris CD, Rufolo P, et al. "Impact of increasing calcium in the diet on nutrient consumption, plasma lipids, and lipoproteins in humans." Am J Clin Nutr 1994; 59(4):900-907.

10. Bucher HC, Cook RJ, Guyatt GH, et al. "Effects of dietary calcium supplementation on blood pressure - a meta-analysis of randomized controlled trials." JAMA 1996; 275(13):1016-1022.

11. Takagi Y, Fukase M, Takata S, et al. "Calcium treatment of essential hypertension in elderly patients evaluated by 24 h monitoring." Am J Hypertens 1991; 4(10 pt 1):836-839.

12. Lyle RM, Melby CL, Hyner GC, et al. "Blood pressure and metabolic effects of calcium supplementation on normotensive white and black men." JAMA 1987; 257(13):1772-1776.

13. Tabuchi Y, Ogihara T, Hashizume K, et al. "Hypotensive effect of long-term oral calcium supplementation in elderly patients with essential hypertension." J Clin Hypertens 1986; 2:254-262.

14. Nieves JW, Komar L, Cosman F, et al. "Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis." Am J Clin Nutr 1998; 67(1):18-24.

15. Dawson-Hughes B, Harris SS, Krall EA, et al. "Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older." N Engl J Med 1997; 337(10):670-676.

16. Fujita T, Ohgitani S & Fujii Y. "Overnight suppression of parathyroid hormone and bone resorption markers by active absorbable algae calcium: a double-blind crossover study." Calcif Tissue Int 1997; 60(6):506-512.

17. McKane WR, Khosla S, Egan KS, et al. "Role of calcium intake in modulating age-related increases in Parathyroid function and bone resorption." J Clin Endocrinol Metab 1996; 81(5):1699-1703.

18. Blumsohn A, Herrington K, Hannon RA, et al. "The effect of calcium supplementation on the circadian rhythm of bone resorption." J Clin Endocrinol Metab 1994; 79(3):730-735.

19. Reid IR, Ames RW, Evans MC, et al. "Effect of calcium supplementation on bone loss in postmenopausal women." N Engl J Med 1993; 328(7):460-464.

20. Chapuy MC, Arlot ME, Duboeuf F, et al. "Vitamin D3 and calcium to prevent hip fractures in elderly women." N Engl J Med 1992; 327(23):1637-1642.

21. Thys-Jacobs S, Starkey P, Bernstein D, et al. "Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms (Premenstrual Syndrome Study Group)." Am J Obstet Gynecol 1998; 179(2):444-452.

22. Swerdloff RS, Wang C. "Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent." Baillieres Clin Endocrinol Metab. 1998 Oct;12(3):501-6.

23. Cunha GR, Hayward SW, Wang YZ. "Role of stroma in carcinogenesis of the prostate." Differentiation. 2002 Dec;70(9-10):473-85

24. Kuhn JM, et al. "Effects of 10 days administration of percutaneous dihydrotestosterone on the pituitary-testicular axis in normal men." J Clin Endocrinol Metab. 1984 Feb;58(2):231-5

25. McConnell JD, et al. "Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia."
J Clin Endocrinol Metab. 1992 Mar;74(3):505-8. 

26. Gormley GJ, et al. "Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers." J Clin Endocrinol Metab. 1990 Apr;70(4):1136-41

27. Rittmaster RS, et al. "Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men." J Clin Endocrinol Metab. 1992 Aug;75(2):484-8. 

28. Thompson IM, et al. "The Influence of Finasteride on the Development of Prostate Cancer." N Engl J Med. 2003 Jun 24

29. Kuhn JM, et al. "Studies on the treatment of idiopathic gynaecomastia with percutaneous dihydrotestosterone." Clin Endocrinol (Oxf). 1983 Oct;19(4):513-20. 

30. Deacon S, English J & Arendt J. "Acute phase-shifting effects of melatonin associated with suppression of core body temperature in humans." Neuroscience 1994; 178(1):32-34.

31. Dollins AB, Zhdanova IV, Wurtman RJ, et al. "Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance." Proc Natl Acad Sci USA 1994; 91(5):1824-1828.

32. Nordlund JJ & Lerner AB. "The effect of oral melatonin on skin color and on the release of pituitary hormones." J Clin Endocrinol Metab 1977; 45(4):768-774.

33. Lissoni P, Barni S, Ardizzoia A, et al. "Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin." Oncology 1992; 49(5):336-339.

34. Lissoni P, Barni S, Cattaneo G, et al. "Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies." Oncology 1991; 48(6):448-450.

35. Cuzzocrea S, Constantino G, Gitto E, et al. "Protective effects of melatonin in ischemic brain injury." J Pineal Res 2000; 29(4):217-227.

36. Lissoni P, et al. "Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial." J Pineal Res. 2003 Aug;35(1):12-5.

37. Weiss JF, Landauer MR. "Protection against ionizing radiation by antioxidant nutrients and phytochemicals." Toxicology. 2003 Jul 15;189(1-2):1-20 

38. Lissoni P, et al. "A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients." Br J Cancer. 1996 Nov;74(9):1466-8.

39. Lissoni P, Barni S, Ardizzoia A, et al. "A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms." Cancer 1994; 73(3):699-701.

40. Short RV. "Melatonin: hormone of darkness (editorial)." BMJ 1993; 307(6910):952-953.

41. Lane EA & Moss HB. "Pharmacokinetics of melatonin in man: first pass hepatic metabolism." J Clin Endocrinol Metab 1985; 61(6):1214-1216.

42. Lissoni P, Barni S, Mandala M, et al. "Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status." Eur J Cancer 1999; 35(12):1688-1692.

43. Lissoni P, Tancini G, Barni S, et al. "Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin." Support Care Cancer 1997; 5:126-129.

44. Ghielmini M, Pagani O, de Jong J, et al. "Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer." Br J Cancer 1999; 80(7):1058-1061.

45. Lissoni P, Barni S, Tancini G, et al. "Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors." Oncology 1995; 52:163-166.

46. Lissoni P, Brivio F, Barni S, et al. "Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension." Anticancer Res 1990; 10:1759-1762.

47. Turjanski AG, Leonik F, Estrin DA, et al. "Scavenging of NO by melatonin." J Am Chem Soc 2000; 122(42):10468-10469.

48. Lissoni P, Barni S, Tancini G, et al. "A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma." Br J Cancer 1994; 69:196-199.

49. Gentry CL, Lukas RJ. "Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure." Curr Drug Target CNS Neurol Disord. 2002 Aug;1(4):359-85.

50. Ke L, Eisenhour CM, Bencherif M, Lukas RJ. "Effects of chronic nicotine treatment on expression of diverse nicotinic acetylcholine receptor subtypes. I. Dose- and time-dependent effects of nicotine treatment." J Pharmacol Exp Ther. 1998 Aug;286(2):825-40.

51. Gilbert DG, Dibb WD, Plath LC, Hiyane SG. "Effects of nicotine and caffeine, separately and in combination, on EEG topography, mood, heart rate, cortisol, and vigilance." Psychophysiology. 2000 Sep;37(5):583-95.

52. Sabbagh MN, Lukas RJ, Sparks DL, Reid RT. "The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease." J Alzheimers Dis. 2002 Aug;4(4):317-25.

53. Mansvelder HD, Keath JR, McGehee DS. "Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas." Neuron. 2002 Mar 14;33(6):905-19.

54. Lebargy F. "Nicotine dependence." Rev Pneumol Clin. 2000 Jun;56(3):177-83

55. Nisell M, Nomikos GG, Svensson TH. "Nicotine dependence, midbrain dopamine systems and psychiatric disorders." Pharmacol Toxicol. 1995 Mar;76(3):157-62

56. Killen JD, Fortmann SP, Schatzberg A, Hayward C, Varady A. "Onset of major depression during treatment for nicotine dependence." Addict Behav. 2003 Apr;28(3):461-70.

© 1998 — 2003 Testosterone, LLC. All Rights Reserved.
PUBLISHED 
Discuss | Rate | Add Favorite | Print Version